GlassScriptPhysician profile
Kilee Lincoln
NPI 1841634755
$2,401.04
in general payments reported to CMS, 2019-2025
22 companies · $476 in 2025
The $476 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $159 · 2021: $421 · 2022: $410 · 2023: $409 · 2024: $325 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $358.73 | 2019-2025 | |
| Pfizer INC. | $335.38 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $331.43 | 2022-2025 | |
| Astellas Pharma US INC | $238.56 | 2022-2025 | Veozah |
| Avion Pharmaceuticals | $186.98 | 2019-2023 | Balcoltra |
| Sumitomo Pharma America, INC. | $177.13 | 2024-2025 | Gemtesa, Myfembree |
| Hologic Sales and Service, LLC | $105.20 | 2019-2024 | Aptima, Affirm Prone Biopsy System |
| Evofem Biosciences, INC. | $97.44 | 2021-2025 | Phexxi, Solosec, Phexx |
| Therapeuticsmd, INC. | $81.27 | 2019-2022 | |
| Sage Therapeutics, LLC | $77.75 | 2024-2025 | Zurzuvae |
| Ethicon US, LLC | $63.29 | 2022-2023 | Harmonic |
| Millicent US INC | $58.18 | 2025 | Femlyv, Intrarosa |
| Organon LLC | $50.39 | 2021-2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $49.25 | 2025 | |
| Amgen INC. | $46.76 | 2019-2025 | Evenity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $40.84 | 2021-2022 | |
| Shield Therapeutics INC | $22.47 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.83 | 2019 | |
| Exeltis, USA INC. | $17.75 | 2025 | Slynd |
| Supernus Pharmaceuticals, INC. | $16.33 | 2025 | Qelbree |
| Novo Nordisk INC | $14.95 | 2019 | |
| Merck Sharp & Dohme LLC | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kilee Lincoln listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.